Home > Search Results: Bauer, Todd M.
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
UAB Digital Repository of Documents 2 records found  Search took 0.02 seconds. 
1.
0 p, 567.1 KB Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : clinical and biomarker results from a phase I trial / Schuler, M. (German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany) ; Berardi, R. (Università Politecnica delle Marche-Ospedali Riuniti) ; Lim, W.-T (National Cancer Centre Singapore) ; de Jonge, M. (Erasmus MC Cancer Center, Rotterdam) ; Bauer, Todd M (Sarah Cannon Research Institute, and Tennessee Oncology) ; Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Gottfried, M. (Oncology Institute of Meir Medical Center) ; Han, J.Y (Center for Lung Cancer, National Cancer Center (Corea del Sud)) ; Lee, D. H. (University of Ulsan College of Medicine (República de Corea)) ; Wollner, M. (Rambam Health Care Campusm (Israel)) ; Hong, David (MD Anderson Cancer Center (Estats Units d'Amèrica)) ; Vogel, A. (Hannover Medical School (Alemanya)) ; Delmonte, A. (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) ; Akimov, Mikhail (Novartis Pharma (Siïssa)) ; Ghebremariam, S. (Oncology Global Development-BDM) ; Cui, X. (Novartis Institutes for Biomedical Research) ; Nwana, N. (Oncology Precision Medicine) ; Giovannini, M. (Novartis Pharmaceuticals Corporation(Estats Units d'Amèrica)) ; Kim, T. M. (Seoul National University Hospital)
Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%-4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. [...]
2020 - 10.1016/j.annonc.2020.03.293
Annals of oncology, Vol. 31 (march 2020) , p. 789-797  
Detailed record - Creative Commons
2.
12 p, 435.5 KB Phase 1 study of capmatinib in MET-positive solid tumor patients : Dose escalation and expansion of selected cohorts / Bang, Yung-Jue (Seoul National University College of Medicine) ; Su, Wu-Chou (National Cheng Kung University Hospital) ; Schuler, Martin (University Duisburg-Essen and German Cancer Consortium (DKTK)) ; Nam, Do-Hyun (Samsung Medical Center) ; Lim, Wan Teck (National Cancer Centre) ; Bauer, Todd M. (PLLC) ; Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Poon, Ronnie Tung Ping (Queen Mary Hospital) ; Hong, David (University of Texas/MD Anderson Cancer Center) ; Lin, Chia-Chi (National Taiwan University Hospital (Taipei, Taiwan)) ; Akimov, Mikhail (Novartis Pharma AG) ; Ghebremariam, Samson (Novartis Pharmaceuticals Corporation) ; Zhao, Sylvia (China Novartis Institutes for Biomedical Research) ; Giovannini, Monica (Novartis Pharmaceuticals Corporation) ; Ma, Brigette (The Chinese University of Hong Kong)
Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor. Herein, we report phase 1 dose-escalation results for capmatinib in advanced MET-positive solid tumor patients and dose expansion in advanced non-lung tumors. [...]
2019 - 10.1111/cas.14254
Cancer Science, Vol. 111 (december 2019) , p. 536-547  
Detailed record - Creative Commons

See also: similar author names
1 Bauer, Th.S.
1 Bauer, Thomas
1 Bauer, Thomas S.
1 Bauer, Todd M
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with